The SGLT-2 Inhibitor Market Size is expected to reach USD 10.21 billion in 2023, rising to USD 20.65 billion by 2033 with an 8.5% CAGR during the forecast period 2024-2033.
According to industry analysts, the global SGLT2 Inhibitor market is predicted to grow significantly in the coming years, owing to several major factors that will influence the market landscape. Among these variables are the rising prevalence of diabetes, a greater emphasis on managing diabetes-related cardiovascular problems, and the ongoing discovery of innovative and more potent SGLT2 inhibitors.The increased global prevalence of diabetes, particularly type 2 diabetes, is a major driver of the expected rise in the SGLT2 inhibitor market. As diabetes rates rise worldwide, an increasing number of patients seek efficient treatment alternatives to control the condition and its complications.
Furthermore, increasing recognition of the cardiovascular advantages associated with SGLT2 inhibitors is projected to drive market growth. Recent research and clinical trials have emphasized the potential cardiovascular benefits of SGLT2 inhibitors beyond glycemic control, which has influenced their use in diabetes care. Another key factor driving market expansion is the ongoing discovery of novel SGLT2 inhibitors with improved efficacy and safety characteristics. Pharmaceutical companies are actively investing in R&D to introduce newer and better SGLT2 inhibitors, giving doctors more alternatives for diabetes management.
Request a sample copy of the report – https://wemarketresearch.com/sample-request/sglt-2-inhibitor-market/1403
SGLT-2 Inhibitor Market Regional Scope
- North America
- Europe
- APAC
- South America
- Middle East
- Africa
SGLT-2 Inhibitor Market Country Scope
The SGLT-2 Inhibitor Market is active in the United States, Canada, the United Kingdom, Germany, France, Italy, Spain, Benelux, Nordic countries, Russia, China, India, Japan, South Korea, Australia, Indonesia, Thailand, Mexico, Brazil, Argentina, Saudi Arabia, the United Arab Emirates, Egypt, South Africa, and Nigeria.
Growth Drivers
The rising prevalence of type 2 diabetes worldwide adds to the growing demand for effective antidiabetic drugs, such as SGLT-2 inhibitors. The inclusion of SGLT-2 inhibitors in treatment guidelines and recommendations by healthcare organizations has changed prescribing patterns and expanded their use in clinical practice. SGLT-2 inhibitors have been shown to have renoprotective benefits in persons with diabetes, delaying the course of kidney damage. This feature has improved its popularity in treating diabetic nephropathy.
SGLT-2 Inhibitor Market Dynamics
The FDA has approved the first class of oral anti-hyperglycemic drugs, SGLT2 inhibitors, for the treatment of diabetes mellitus. SGLT2 inhibitors are a class of prescription medications that the FDA has approved for use in people with type 2 diabetes to help them control their blood sugar levels through diet and exercise. Canagliflozin, dapagliflozin, and empagliflozin are all SGLT2 inhibitors. Both solo formulations and combos with other diabetes drugs, such as metformin, are available. SGLT 2 inhibitors have a unique mode of action: they lower blood sugar by boosting insulin production while also increasing sugar excretion from the kidney.
SGLT-2 Inhibitor Market Opportunities
The global SGLT-2 market is estimated to grow during the forecast period due to the increased prevalence of diabetes mellitus. The FDA has approved the most recent class of anti-hyperglycemic medications: sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors function through a novel method that reduces renal tubular glucose reabsorption, lowering blood glucose levels without causing insulin release. More clinical trials and increased research and development efforts have made it possible for various innovative molecules, including dapagliflozin and empagliflozin, which are currently in clinical trials, to join the market in the future as ground-breaking medicines.
Buy Now SGLT-2 Inhibitor Market Report – https://wemarketresearch.com/purchase/sglt-2-inhibitor-market/1403?license=single
About We Market Research
We Market Research is a leading provider of comprehensive market research solutions that assist businesses in making informed decisions and staying ahead of the competition in today’s ever-changing marketplace. With our extensive knowledge and cutting-edge methods, we assist our customers in gaining deep insights into their target markets, consumers, and competitors.
Our firm understands that great business strategies are based on accurate and actionable data. That is why we specialize in conducting in-depth research and analysis across several industries, enabling our clients to identify market trends, assess demand and supply dynamics, and identify development opportunities.
Contact us
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
